Abstract
Résumé
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyReferences
Virani SA, Dent S, Johnson C, et al. Canadian Cardiovascular Society Position Statement: evaluation of patients at risk of CV complications of cancer therapy. Presented at: the Canadian Cardiovascular Congress. October 24-26, 2015; Toronto, Ontario, Canada.
- American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.J Clin Oncol. 2009; 27: 127-145
- Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.Ann Oncol. 2012; 23: 155-166
- Adding “value” to clinical practice guidelines.Can Fam Physician. 2007; 53: 1326-1327
- Cardioprotective interventions for cancer patients receiving anthracyclines.Cochrane Database Syst Rev. 2011; : CD003917
- Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.J Clin Oncol. 1997; 15: 1318-1332
- Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.J Clin Oncol. 2007; 25: 493-500
- Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer [in Chinese].Zhonghua Zhong Liu Za Zhi. 2013; 35: 936-940
- Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up.Am J Hematol. 2010; 85: 894-896
- Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. The OVERCOME Trial.J Am Coll Cardiol. 2013; 61: 2355-2362
- Protective effects of carvedilol against anthracycline-induced cardiomyopathy.J Am Coll Cardiol. 2006; 48: 2258-2262
- Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study.Int J Cardiol. 2013; 167: 2306-2310
- Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia.J Card Fail. 2012; 18: 607-613
Pituskin E, Mackey JR, Koshman S, et al. MANTICORE 101: multidisciplinary approach to novel therapies in cardio-oncology research. Oral presentation at: San Antonio Breast Cancer Symposium. December 9-12, 2015; San Antonio, TX
Gulati G, Heck SL, Hoffman P, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): primary results of a randomized, 2 × 2 factorial, placebo-controlled, double-blind clinical trial. Paper presented at: American Heart Association 2015 Scientific Sessions. November 11, 2015; Orlando, FL.
- Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.J Am Coll Cardiol. 2012; 60: 2384-2390
- Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.Can J Cardiol. 2015; 31: 302-307
- Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.J Am Coll Cardiol. 2011; 58: 988-989
- Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management.Can J Cardiol. 2006; 22: 23-45
- Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.Lancet. 2000; 355: 1575-1581
- Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.Lancet. 2009; 374: 1840-1848
- Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.Circulation. 1999; 100: 2312-2318
- Major beta blocker mortality trials in chronic heart failure: a critical review.Heart. 1999; 82: IV14-IV22
- Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.J Am Heart Assoc. 2014; 3: e000472
- Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol. 2012; 30: 3792-3799
- The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.Breast Cancer Res Treat. 2008; 107: 443-450
- Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.J Clin Oncol. 2013; 31: 3673-3680
- Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.J Am Coll Cardiol. 2010; 55: 213-220
- Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?.Oncologist. 2012; 17: 917-924
- Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.Lancet. 1996; 347: 297-299
- Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.Ann Oncol. 2002; 13: 699-709
- Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.J Heart Lung Transplant. 2005; 24: 2196-2201
- Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.J Clin Oncol. 2010; 28: 3910-3916
- Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.Circulation. 2004; 109: 2749-2754
- Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.Circulation. 2006; 114: 2474-2481
- Chemotherapy-induced cardiotoxicity: role of the tissue Doppler in the early diagnosis of left ventricular dysfunction.Anticancer Drugs. 2011; 22: 468-472
- Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.J Am Coll Cardiol. 2013; 61: 77-84
- Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review.Circ Cardiovasc Imaging. 2013; 6: 1080-1091
- Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection.Eur Heart J Cardiovasc Imaging. 2014; 15: 324-331
Article info
Publication history
Footnotes
See article by Abdel-Qadir et al., pages 921-925 of this issue.
See page 929 for disclosure information.